Electrophilic warhead-based design of compounds preventing NLRP3 inflammasome-dependent pyroptosis

Journal of Medicinal Chemistry

Volumn 57, Issue 24, 2014, Pages 10366-10382

  Cocco, Mattia ^a   Garella, Davide ^a   Di Stilo, Antonella ^a   Borretto, Emily ^a   Stevanato, Livio ^a   Giorgis, Marta ^a   Marini, Elisabetta ^a   Fantozzi, Roberto ^a   Miglio, Gianluca ^a   Bertinaria, Massimo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 [(2 CHLOROPHENYL)(HYDROXY)METHYL] N PROPYLACRYLAMIDE; 2 [(2 CHLOROPHENYL)(HYDROXY)METHYL]ACRYLIC ACID; 2 [(2 CHLOROPHENYL)(HYDROXY)METHYL]ACRYLONITRILE; 2 [(2 CHLOROPHENYL)(HYDROXY)METHYL]PENT 1 EN 3 ONE; 2 [(2,4 DICHLOROPHENYL)(HYDROXY)METHYL]ACRYLONITRILE; 2 [(2,6 DICHLOROPHENYL)(HYDROXY)METHYL]ACRYLONITRILE; 2 [HYDROXY(NAPHTHALEN 1 YL)METHYL]ACRYLONITRILE; 2 [HYDROXY(PHENYL)METHYL]ACRYLONITRILE; 2 [HYDROXY(PYRIDIN 2 YL)METHYL]ACRYLONITRILE; 7 OXOZEANEOL; APOPTOSIS INHIBITOR; CARBONYL DERIVATIVE; CRYOPYRIN; ETHYL 2 [(2 BROMOPHENYL)(HYDROXY)METHYL]ACRYLATE; ETHYL 2 [(2 CHLOROPHENYL)(HYDROXY)METHYL] 3 PHENYL ACRYLATE; ETHYL 2 [(2 CHLOROPHENYL)(HYDROXY)METHYL]ACRYLATE; ETHYL 2 [(2 CHLOROPHENYL)(HYDROXY)METHYL]BUT 2 ENOATE; ETHYL 2 [(2 FLUOROPHENYL)(HYDROXY)METHYL]ACRYLATE; ETHYL 2 [(2,4 DICHLOROPHENYL)(HYDROXY)METHYL]ACRYLATE; ETHYL 2 [(2,6 DICHLOROPHENYL)(HYDROXY)METHYL]ACRYLATE; ETHYL 2 [(3 CHLOROPHENYL)(HYDROXY)METHYL]ACRYLATE; ETHYL 2 [(4 CHLOROPHENYL)(HYDROXY)METHYL]ACRYLATE; ETHYL 2 [(HYDROXY)(2 METHOXYPHENYL)METHYL]ACRYLATE; ETHYL 2 [(PHENYL)(HYDROXY)METHYL]ACRYLATE; ETHYL 2 [HYDROXY(2 NITROPHENYL)METHYL]ACRYLATE; ETHYL 2 [HYDROXY(PYRIDIN 2 YL)METHYL]ACRYLATE; INTERLEUKIN 1BETA CONVERTING ENZYME INHIBITOR; NITRILE; RESATORVID; UNCLASSIFIED DRUG; UNINDEXED DRUG; ADENOSINE TRIPHOSPHATASE; ANTIINFLAMMATORY AGENT; CARRIER PROTEIN; ENZYME INHIBITOR; ETHYL 2-((2-CHLOROPHENYL)(HYDROXY)METHYL)ACRYLATE; INFLAMMASOME; INTERLEUKIN 1BETA CONVERTING ENZYME; METHACRYLIC ACID DERIVATIVE; NLRP3 PROTEIN, HUMAN;

ALKYLATION; ALLYLIC REARRANGEMENT; ANTIOXIDANT RESPONSIVE ELEMENT; APOPTOSIS; ARTICLE; CATALYST; CELL VIABILITY; CHEMICAL REACTION KINETICS; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG DESIGN; DRUG EFFICACY; DRUG SYNTHESIS; ELECTROPHILICITY; HUMAN; HUMAN CELL; MICHAEL ADDITION; PHYSICAL CHEMISTRY; PROTON NUCLEAR MAGNETIC RESONANCE; REACTION TIME; STOICHIOMETRY; STRUCTURE ACTIVITY RELATION; THIN LAYER CHROMATOGRAPHY; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; KIDNEY TUBULE; MACROPHAGE; PATHOLOGY;

ADENOSINE TRIPHOSPHATASES; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; CARRIER PROTEINS; CASPASE 1; CELL PROLIFERATION; CELLS, CULTURED; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; INFLAMMASOMES; KIDNEY TUBULES; MACROPHAGES; METHACRYLATES;

EID: 84920133467     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501072b     Document Type: Article

References (62)

1. Chen, Y.; Smith, M. R.; Thirumalai, K.; Zychlinsky, A. A bacterial invasin induces macrophage apoptosis by binding directly to ICE EMBO J. 1996, 15, 3853-3860
2. Hilbi, H.; Moss, J. E.; Hersh, D.; Chen, Y.; Arondel, J.; Banerjee, S.; Flavell, R. A.; Yuan, J.; Sansonetti, P. J.; Zychlinsky, A. Shigella-induced apoptosis is dependent on caspase-1 which binds to IpaB J. Biol. Chem. 1998, 273, 32895-32900
3. Fink, S. L.; Cookson, B. T. Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages Cell. Microbiol. 2006, 8, 1812-1825
4. Brennan, M. A.; Cookson, B. T. Salmonella induces macrophage death by caspase-1-dependent necrosis Mol. Microbiol. 2000, 38, 31-40
5. Lamkanfi, M.; Dixit, V. M. Mechanism and functions of inflammasomes Cell 2014, 157, 1013-1022
6. Monack, D. M.; Detweiler, C. S.; Falkow, S. Salmonella pathogenicity island 2-dependent macrophage death is mediated in part by the host cysteine protease caspase-1 Cell. Microbiol. 2001, 3, 825-837
7. Frantz, S.; Ducharme, A.; Sawyer, D.; Rohde, L. E.; Kobzik, L.; Fukazawa, R.; Tracey, D.; Allen, H.; Lee, R. T.; Kelly, R. A. Targeted deletion of caspase-1 reduces early mortality and left ventricular dilatation following myocardial infarction J. Mol. Cell. Cardiol. 2003, 35, 685-694
8. Hoegen, T.; Tremel, N.; Klein, M.; Angele, B.; Wagner, H.; Kirschning, C.; Pfister, H. W.; Fontana, A.; Hammerschmidt, S.; Koedel, U. The NLRP3 inflammasome contributes to brain injury in pneumococcal meningitis and is activated through ATP-dependent lysosomal cathepsin B release J. Immunol. 2011, 187, 5440-5451
9. Gulbransen, B. D.; Bashashati, M.; Hirota, S. A.; Gui, X.; Roberts, J. A.; MacDonald, J. A.; Muruve, D. A.; McKay, D. M.; Beck, P. L.; Mawe, G. M.; Thompson, R. J.; Sharkey, K. A. Activation of neuronal P2X7 receptor-pannexin-1 mediates death of enteric neurons during colitis Nature Med. 2012, 18, 600-604
10. Halle, A.; Hornung, V.; Petzold, G. C.; Stewart, C. R.; Monks, B. G.; Reinheckel, T.; Fitzgerald, K. A.; Latz, E.; Moore, K. J.; Golenbock, D. T. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta Nature Immunol. 2008, 9, 857-865
11. Heneka, M. T.; Kummer, M. P.; Stutz, A.; Delekate, A.; Schwartz, S.; Vieira-Saecker, A.; Griep, A.; Axt, D.; Remus, A.; Tzeng, T. C.; Gelpi, E.; Halle, A.; Korte, M.; Latz, E.; Golenbock, D. T. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice Nature 2013, 493, 674-678
12. Shi, F.; Yang, Y.; Kouadir, M.; Fu, Y.; Yang, L.; Zhou, X.; Yin, X.; Zhao, D. Inhibition of phagocytosis and lysosomal acidification suppresses neurotoxic prion peptide-induced NALP3 inflammasome activation in BV2 microglia J. Neuroimmunol. 2013, 260, 121-125
13. Codolo, G.; Plotegher, N.; Pozzobon, T.; Brucale, M.; Tessari, I.; Bubacco, L.; de Bernard, M. Triggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies PLoS One 2013, 8, e55375
14. Martinon, F.; Burns, K.; Tschopp, J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta Mol. Cell 2002, 10, 417-426
15. Rathinam, V. A.; Vanaja, S. K.; Fitzgerald, K. A. Regulation of inflammasome signaling Nature Immunol. 2012, 13, 333-342
16. Sutterwala, F. S.; Haasken, S.; Cassel, S. L. Mechanism of NLRP3 inflammasome activation Ann. N. Y. Acad. Sci. 2014, 1319, 82-95
17. Mariathasan, S.; Weiss, D. S.; Newton, K.; McBride, J.; O'Rourke, K.; Roose-Girma, M.; Lee, W. P.; Weinrauch, Y.; Monack, D. M.; Dixit, V. M. Cryopyrin activates the inflammasome in response to toxins and ATP Nature 2006, 440, 228-232
18. Bauernfeind, F. G.; Horvath, G.; Stutz, A.; Alnemri, E. S.; MacDonald, K.; Speert, D.; Fernandes-Alnemri, T.; Wu, J.; Monks, B. G.; Fitzgerald, K. A.; Hornung, V.; Latz, E. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression J. Immunol. 2009, 183, 787-791
19. Dinarello, C. A.; Simon, A.; Van der Meer, J. W. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases Nature Rev. Drug Discovery 2012, 11, 633-652
20. López-Castejón, G.; Pelegrín, P. Current status of inflammasome blockers as anti-inflammatory drugs Expert Opin. Invest. Drugs 2012, 21, 995-1007
21. Walsh, J. G.; Muruve, D. A.; Power, C. Inflammasomes in the CNS Nature Rev. Neurosci. 2014, 15, 84-97
22. So, A.; Ives, A.; Joosten, L. A. B.; Busso, N. Targeting inflammasomes in rheumatic diseases Nature Rev. Rheumatol. 2013, 9, 391-399
23. Agostini, L.; Burns, K.; McDermott, M. F.; Hawkins, P. N.; Tschopp, J. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder Immunity 2004, 20, 319-325
24. Goldbach-Mansky, R.; Dailey, N. J.; Canna, S. W.; Gelabert, A.; Jones, J.; Rubin, B. I.; Kim, H. J.; Brewer, C.; Zalewski, C.; Wiggs, E.; Hill, S.; Turner, M. L.; Karp, B. I.; Aksentijevich, I.; Pucino, F.; Penzak, S. R.; Haverkamp, M. H.; Stein, L.; Adams, B.; Moore, T. L.; Fuhlbrigge, R. C.; Shaham, B.; Jarvis, J. N.; O'Neil, K.; Vehe, R. K.; Beitz, L. O.; Gardner, G.; Hannan, W. P.; Warren, R. W.; Horn, W.; Cole, J..L; Paul, S. M.; Hawkins, P. N.; Pham, T. H.; Snyder, C.; Wesley, R. A.; Hoffmann, S. C.; Holland, S. M.; Butman, J. A.; Kastner, D. L. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition N. Engl. J. Med. 2006, 355, 581-592
25. Gattorno, M.; Tassi, S.; Carta, S.; Delfino, L.; Ferlito, F.; Pelagatti, M. A.; D'Osualdo, A.; Buoncompagni, A.; Alpigiani, M. G.; Alessio, M.; Martini, A.; Rubartelli, A. Pattern of interleukin-1β secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations Arthritis Rheum. 2007, 56, 3138-3148
26. Di Virgilio, F. The therapeutic potential of modifying inflammasomes and NOD-like receptors Pharmacol. Rev. 2013, 65, 872-905
27. Davis, B. K.; Wen, H.; Ting, J. P.-Y. The inflammasome NLRs in immunity, inflammation and associated diseases Annu. Rev. Immunol. 2011, 29, 707-735
28. De Nardo, D.; Latz, E. NLRP3 inflammasomes link inflammation and metabolic diseases Trends Immunol. 2011, 32, 373-379
29. Haneklaus, M.; O'Neill, L. AJ; Coll, R. C. Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developments Curr. Opin. Immunol. 2013, 25, 40-45
30. Gong, Y. N.; Wang, X.; Wang, J.; Yang, Z.; Li, S.; Yang, J.; Liu, L.; Lei, X.; Shao, F. Chemical probing reveals insights into the signaling mechanism of inflammasome activation Cell Res. 2010, 20, 1289-1305
31. Juliana, C.; Fernandes-Alnemri, T.; Wu, J.; Datta, P.; Solorzano, L.; Yu, J. W.; Meng, R.; Quong, A. A.; Latz, E.; Scott, C. P.; Alnemri, E. S. Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome J. Biol. Chem. 2010, 285, 9792-9802
32. He, Y.; Varandarajan, S.; Munoz-Planillo, R.; Burberry, A.; Nakamura, Y.; Nunez, G. 3,4-Methylenedioxy-β-nitrostyrene inhibits NLRP3 activation by blocking assembly of the inflammasome J. Biol. Chem. 2014, 289, 1142-1150
33. Wilson, A. J.; Kerns, J. K.; Callahn, J. F.; Moody, C. J. Keep calm, and carry on covalently J. Med. Chem. 2013, 56, 7463-7476
34. Kalguktar, A. S.; Dalvie, D. K. Drug discovery for a new generation of covalent drugs Expert Opin. Drug Discovery 2012, 7, 561-581
35. Singh, J.; Petter, R. C.; Baillie, T. A.; Whitty, A. The resurgence of covalent drugs Nature Rev. Drug Discovery 2011, 10, 307-317
36. Johansson, M. H. Reversible Michael additions: covalent inhibitors and prodrugs Mini-Rev. Med. Chem. 2012, 12, 1330-1344
37. Amslinger, S. The tunable functionality of α,β-unsaturated carbonyl compounds enables their differential application in biological systems ChemMedChem 2010, 5, 351-356
38. Avonto, C.; Taglialatela-Scafati, O.; Pollastro, F.; Minassi, A.; Di Marzo, V.; De Petrocellis, L.; Appendino, G. An NMR spectroscopic method to identify and classify thiol-trapping agents: revival of Michael acceptors for drug discovery? Angew. Chem., Int. Ed. 2011, 50, 467-471
39. Miller, R. M.; Paavilainen, V. O.; Krishnan, S.; Serafimova, I. M.; Taunton, J. Electrophilic fragment-based design of reversible covalent kinase inhibitors J. Am. Chem. Soc. 2013, 135, 5298-5301
40. Zheng, S.; Santosh Laxmi, Y. R.; David, E.; Dinkova-Kostova, A. T.; Shiavoni, K. H.; Ren, Y.; Trevino, I.; Bumeister, R.; Ojima, I.; Wigley, W. C.; Bliska, J. B.; Mierke, D. F.; Honda, T. Synthesis, chemical reactivity as Michael acceptors, and biological potency of monocyclic cyanoenones, novel and highly potent anti-inflammatory and cytoprotective agents J. Med. Chem. 2012, 55, 4837-4846
41. Kathman, S. G.; Xu, Z.; Statsyuk, A. V. A fragment-based method to discover irreversible covalent inhibitors of cysteine proteases J. Med. Chem. 2014, 57, 4969-4974
42. Al-Rifai, N.; Rücker, H.; Amslinger, S. Opening or closing the lock? When reactivity is the key to biological activity Chem.-Eur. J. 2013, 19, 15384-15395
43. Zhao, M. X.; Wei, Y.; Shi, M. Morita-Baylis-Hillman Reaction. In The Chemistry of the Morita-Baylis-Hillman Reaction; RSC Catalysis Series No. 8; Shi, M.; Wang, F. J.; Zhao, M. X.; Wei, Y., Eds; RSC Publishing: Cambridge, 2011; pp 1-78.
44. Yu, C.; Liu, B.; Hu, L. Efficient Baylis-Hillman reaction using stoichiometric base catalyst and an aqueous medium J. Org. Chem. 2001, 66, 5413-5418
45. Aggarwal, V. K.; Dean, D. K.; Mereu, A.; Williams, R. Rate acceleration of the Baylis-Hillman reaction in polar solvents (water and formamide). Dominant role of hydrogen bonding, not hydrophobic effects, is implicated J. Org. Chem. 2002, 67, 510-514
46. Ranatunga, S.; Kim, J. S.; Pal, U.; Del Valle, J. R. An ester enolate-Claisen rearrangement route to substituted 4-alkylideneprolines. Studies toward a definitive structural revision of lucentamycin A J. Org. Chem. 2011, 76, 8962-8976
47. 2-promoted stereoselective aldol coupling Helv. Chim. Acta 2004, 87, 2359-2363
48. Hentze, H.; Lin, X. Y.; Choi, M. S.; Porter, A. G. Critical role for cathepsin B in mediating caspase-1-dependent interleukin-18 maturation and caspase-1-independent necrosis triggered by the microbial toxin nigericin Cell Death Differ. 2003, 10, 956-968
49. Deane, P. O.; Guthrie, J. J.; Kaye, P. T.; Whittaker, R. E. Regio- and diastereoselectivity in the thiomethylation of α-(1-hydroxyalkyl)acrylate derivatives Synth. Commun. 1998, 28, 2601-2611
50. Sakakura, A.; Takayanagi, Y.; Shimogawa, H.; Kigoshi, H. Jolkinolide D pharmacophore: synthesis and reaction with biomolecules Tetrahedron 2004, 60, 7067-7075
51. Maydt, D.; De Spirt, S.; Muschelknautz, C.; Sthal, W.; Müller, T. J. J. Chemical reactivity and biological activity of chalcones and other α,β-unsaturated carbonyl compounds Xenobiotica 2013, 43, 711-718
52. Ma, Q. Role of Nrf2 in Oxidative Stress and Toxicity Annu. Rev. Pharmacol. Toxicol. 2013, 53, 401-426
53. Bode, M. L.; Kaye, P. T. Indolizine studies. Part 2. Synthesis and NMR spectroscopic analysis of 2-substituted indolizines J. Chem. Soc., Perkin Trans. 1 1993, 15, 1809-1813
54. Yuan, K.; Song, H. L.; Hu, Y.; Wu, X. Y. Chiral phosphinthiourea-catalyzed asymmetric Morita-Baylis-Hillman reactions of acrylates with aromatic aldehydes Tetrahedron Lett. 2009, 65, 8185-8190
55. Barbosa, T. P.; Junior, C. G. L.; Silva, F. P. L.; Lopes, H. M.; Figueirido, L. R. F.; Sousa, S. C. O.; Batista, G. N.; Da Silva, T. G.; Silva, T. M. S.; De Oliveira, M. R.; Vasconcellos, M. L. L. Improved synthesis of seven aromatic Baylis-Hillman adducts (BHA): evaluation against Artemia saliva Leach. and Leishmania chagasi Eur. J. Med. Chem. 2009, 44, 1726-1730
56. Singh, S. A.; Shat, S. V. Antimicrobial potential of 3-hydroxy-2-methylene-3-phenylpropionic acid derivatives Acta Pharm. 2011, 61, 447-455
57. Coehlo, F.; Veronese, D.; Pavam, C. H.; de Paula, V. I.; Buffon, R. Palladium-catalyzed carbonylative cyclization of Baylis-Hillman adducts. An efficient approach for the stereoselective synthesis of 3-alkenyl phthalides Tetrahedron 2006, 62, 4563-4572
58. Reddy, L. R.; Rao, K. R. Rate acceleration of the Baylis-Hillman reaction using crystalline cyclodextrin complexes Org. Prep. Proced. Int. 2000, 32, 185-203
59. Singha Roy, S. J.; Mukherjee, S. Enantioselctive desymmetrization of prochiral 1,3-dinitropropanes via organocatalytic allylic alkylation Chem. Commun. 2014, 50, 121-123
60. Drewes, S. E.; Emslie, N. D. Necic acid synthesis. Part 1. Total synthesis of integerrinic acid J. Chem. Soc., Perkin Trans. 1 1982, 2079-2083
61. Thornberry, N. A. Interleukin-1β converting enzyme Methods Enzymol. 1994, 244, 615-631
62. Gierse, J. K.; Koboldt, C. M.; Walker, M. C.; Seibert, K.; Isakson, P. C. Kinetic basis for selective inhibition of cyclo-oxygenases Biochem. J. 1999, 339, 607-614